What is it about?
Bosutinib inhibited the growth of the cysts in the kidney, but the treatment was associated with adverse events (namely diarrhoea)
Featured Image
Why is it important?
It is the first clinical study with tyrosine kinase inhibitor in autosomal dominant polycystic kidney disease. It is a proof of concept that inhibition of tyrosine kinases in autosomal dominant polycystic kidney disease can, in principle, work
Perspectives
As the main problem of the study were side effects search for other better tolerated and similarly effective tyrosine kinase inhibitors is warranted
Vladimir Tesar
Read the Original
This page is a summary of: Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease, Journal of the American Society of Nephrology, August 2017, American Society of Nephrology,
DOI: 10.1681/asn.2016111232.
You can read the full text:
Contributors
The following have contributed to this page
